View
Page
Welcome to the new Abzena stream forum! Messages posted in the Abzena stream will be logged here for posterity.
"FY16 results were strong, with 28% like-for-like total revenue growth reported (74% growth including the £2.7m contribution from its acquisitions late 2015). It has been a pivotal year for Abzena as it has expanded its business to provide a broad range of services from antibody discovery through to GMP manufacturing for Phase I/II trials. Alongside this, its clinical Abzena inside pipeline continues to grow, with 11 products now in the clinic and progressing toward commercialisation, most notably GS-5745 in gastric cancer." Note out from Edison yesterday on research tree
Latest from the Community...
Latest from the Community...
Latest from the Community...